Pharvaris Pill Offers Quick Relief for Patients Experiencing Rare Swelling Attacks, According to Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy KALV?
Source: Benzinga
Pharvaris Phase 3 Trial Results: Pharvaris N.V. announced positive topline data from the RAPIDe-3 Phase 3 trial of deucrictibant, showing significant improvements in the on-demand treatment of hereditary angioedema (HAE) attacks, including faster symptom relief compared to placebo.
Market Authorization Plans: The data from the trial will support marketing authorization applications planned for submission starting in the first half of 2026, as the company aims to bring deucrictibant to market.
Competitive Landscape: The approval of competing treatments for HAE, such as Ionis Pharmaceuticals' Dawnzera and KalVista Pharmaceuticals' Ekterly, highlights the growing market for HAE therapies, with both products demonstrating significant efficacy in reducing attack rates.
Stock Performance: Following the announcement, Pharvaris shares rose by 12.32%, reflecting positive investor sentiment regarding the trial results and the potential market impact of deucrictibant.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.460
Low
29.00
Averages
34.38
High
39.00
Current: 16.460
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
- Product Revenue Growth: KalVista Pharmaceuticals achieved $49.1 million in global net product revenue for the eight-month transition period ending December 31, 2025, including $35.4 million in the fourth quarter, indicating steady growth since the launch of EKTERLY, although still in the early stages.
- Rising Operating Expenses: The company's operating expenses surged to $160.2 million, a 43% increase from $117 million in the prior year, primarily driven by the costs associated with commercial launch activities, reflecting the high costs of market promotion.
- Reduced R&D Spending: Research and development expenses were $33.4 million, down 36% from $52.2 million in the prior year, indicating a more cautious spending strategy on new product development in response to current financial pressures.
- Strong Cash Position: As of December 31, 2025, KalVista reported $300 million in cash and investments, believed to be sufficient to fund operations under the current plan, although the company has not yet provided long-term financial guidance.
See More
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Company Overview: Kalvista Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs.
Financial Report: The company reported earnings of $2.03 per share for the eight months ending December 31, 2025.
See More
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
- Revenue Growth: KalVista reported $49.1 million in global net product revenue for EKTERLY® (sebetralstat) for the eight months ending December 31, 2025, indicating strong market demand and rapid product adoption, which is expected to lay the groundwork for future profitability.
- Patient Initiation Metrics: By February 28, 2026, the company received 1,702 patient start forms in the US, representing nearly 20% of the total US patient population, and activated 724 unique prescribers, demonstrating EKTERLY's swift market penetration and acceptance.
- International Market Expansion: EKTERLY's launch in Japan, facilitated by partner Kaken Pharmaceutical Co., Ltd., has been listed on the National Health Insurance drug reimbursement price list, marking a significant step in the company's global market expansion and enhancing its international competitiveness.
- Significant Clinical Progress: The company completed enrollment in the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2 to 11 a full year ahead of schedule, with plans to file a US new drug application in Q3 2026, further solidifying EKTERLY's position as a foundational therapy for HAE management.
See More
KalVista Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: KalVista Pharmaceuticals reported a Q4 GAAP EPS of -$2.03, which may not be directly comparable to estimates, but revenue of $49.08 million exceeded expectations by $16.79 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company had approximately $300.2 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the next few years and supporting its strategy towards profitability.
- EKTERLY Sales Outlook: The anticipated cash reserves and projected revenues from EKTERLY sales are expected to fund the company through to profitability, reflecting confidence in the product's market potential.
- Future Growth Strategy: KalVista Pharmaceuticals aims to drive the next stage of growth by expanding EKTERLY's pediatric label, a strategy that not only broadens market coverage but could significantly enhance the company's future revenue potential.
See More
KALVISTA PHARMACEUTICALS INC REPORTS $49.1 MILLION IN NET PRODUCT REVENUE FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
- Company Overview: Kalvista Pharmaceuticals has reported a net product revenue of $49.1 million for the eight-month period ending December 31, 2025.
- Financial Performance: The revenue figure indicates the company's performance in the pharmaceutical market during the specified timeframe.
See More
KalVista Pharmaceuticals Set to Announce Q4 Earnings on March 25
- Earnings Announcement: KalVista Pharmaceuticals is set to release its Q4 earnings report on March 25 before market open, with consensus EPS estimate at -$0.53 and revenue estimate at $32.29 million, indicating a cautious market outlook on the company's financial performance.
- EPS Upward Revisions: Over the past three months, KalVista's EPS estimates have seen six upward revisions with no downward adjustments, reflecting growing analyst confidence in the company's future profitability, which could positively impact its stock price.
- Revenue Estimate Adjustments: Similarly, revenue estimates have experienced five upward revisions without any downward changes, suggesting an optimistic market expectation for KalVista's sales growth in upcoming quarters, potentially attracting more investor interest.
- Market Analysis Overview: While KalVista shows growth potential, analysts caution about certain caveats, particularly regarding the next stage of growth tied to pediatric label expansion, urging investors to carefully assess the associated risks and rewards.
See More
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
- Product Revenue Growth: KalVista Pharmaceuticals achieved $49.1 million in global net product revenue for the eight-month transition period ending December 31, 2025, including $35.4 million in the fourth quarter, indicating steady growth since the launch of EKTERLY, although still in the early stages.
- Rising Operating Expenses: The company's operating expenses surged to $160.2 million, a 43% increase from $117 million in the prior year, primarily driven by the costs associated with commercial launch activities, reflecting the high costs of market promotion.
- Reduced R&D Spending: Research and development expenses were $33.4 million, down 36% from $52.2 million in the prior year, indicating a more cautious spending strategy on new product development in response to current financial pressures.
- Strong Cash Position: As of December 31, 2025, KalVista reported $300 million in cash and investments, believed to be sufficient to fund operations under the current plan, although the company has not yet provided long-term financial guidance.
See More
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Company Overview: Kalvista Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs.
Financial Report: The company reported earnings of $2.03 per share for the eight months ending December 31, 2025.
See More
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
- Revenue Growth: KalVista reported $49.1 million in global net product revenue for EKTERLY® (sebetralstat) for the eight months ending December 31, 2025, indicating strong market demand and rapid product adoption, which is expected to lay the groundwork for future profitability.
- Patient Initiation Metrics: By February 28, 2026, the company received 1,702 patient start forms in the US, representing nearly 20% of the total US patient population, and activated 724 unique prescribers, demonstrating EKTERLY's swift market penetration and acceptance.
- International Market Expansion: EKTERLY's launch in Japan, facilitated by partner Kaken Pharmaceutical Co., Ltd., has been listed on the National Health Insurance drug reimbursement price list, marking a significant step in the company's global market expansion and enhancing its international competitiveness.
- Significant Clinical Progress: The company completed enrollment in the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2 to 11 a full year ahead of schedule, with plans to file a US new drug application in Q3 2026, further solidifying EKTERLY's position as a foundational therapy for HAE management.
See More
KalVista Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: KalVista Pharmaceuticals reported a Q4 GAAP EPS of -$2.03, which may not be directly comparable to estimates, but revenue of $49.08 million exceeded expectations by $16.79 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company had approximately $300.2 million in cash, cash equivalents, and marketable securities, ensuring operational funding for the next few years and supporting its strategy towards profitability.
- EKTERLY Sales Outlook: The anticipated cash reserves and projected revenues from EKTERLY sales are expected to fund the company through to profitability, reflecting confidence in the product's market potential.
- Future Growth Strategy: KalVista Pharmaceuticals aims to drive the next stage of growth by expanding EKTERLY's pediatric label, a strategy that not only broadens market coverage but could significantly enhance the company's future revenue potential.
See More
KALVISTA PHARMACEUTICALS INC REPORTS $49.1 MILLION IN NET PRODUCT REVENUE FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
- Company Overview: Kalvista Pharmaceuticals has reported a net product revenue of $49.1 million for the eight-month period ending December 31, 2025.
- Financial Performance: The revenue figure indicates the company's performance in the pharmaceutical market during the specified timeframe.
See More
KalVista Pharmaceuticals Set to Announce Q4 Earnings on March 25
- Earnings Announcement: KalVista Pharmaceuticals is set to release its Q4 earnings report on March 25 before market open, with consensus EPS estimate at -$0.53 and revenue estimate at $32.29 million, indicating a cautious market outlook on the company's financial performance.
- EPS Upward Revisions: Over the past three months, KalVista's EPS estimates have seen six upward revisions with no downward adjustments, reflecting growing analyst confidence in the company's future profitability, which could positively impact its stock price.
- Revenue Estimate Adjustments: Similarly, revenue estimates have experienced five upward revisions without any downward changes, suggesting an optimistic market expectation for KalVista's sales growth in upcoming quarters, potentially attracting more investor interest.
- Market Analysis Overview: While KalVista shows growth potential, analysts caution about certain caveats, particularly regarding the next stage of growth tied to pediatric label expansion, urging investors to carefully assess the associated risks and rewards.
See More
